Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples